# CUREXO

CUREXO is an other based in Seoul, South Korea.

## Overview

- **Organization type:** other
- **Headquarters:** Seoul, South Korea
- **Region:** Asia
- **Address:** Seoul, South Korea
- **Assets under management:** Undisclosed
- **Website:** curexo.com
- **LinkedIn:** https://www.linkedin.com/company/curexo

## Regulatory record

- **Reports private funds:** No

## About

큐렉소(CUREXO)는 첨단 기술을 기반으로 차별화된 의료 솔루션을 제공하는 의료로봇 전문기업입니다. 주요 사업으로 인공관절 수술로봇 'CUVIS-joint', 척추 수술로봇 'CUVIS-spine', 보행재활로봇 'MorningWalk'를 개발 및 공급하고 있습니다. 서울시 송파구에 본사를 두고 있습니다.

## Sectors

- Medical Robotics
- Surgical Robotics
- Rehabilitation Robotics

## Offices

- India

## People

- Jae-joon Lee — CEO

## Questions

### Who runs investment decisions at CUREXO?

CUREXO is a publicly traded operating company, not an asset manager or family office. Capital-allocation and strategic decisions are made by CEO Jae-joon Lee and the board of directors, with reporting obligations to KOSDAQ shareholders. The firm does not manage third-party capital or run an investment portfolio.

### How does CUREXO source its commercial pipeline?

CUREXO sources hospital and distributor accounts through a mix of direct in-country subsidiaries — including an India subsidiary established in 2025 — and exclusive distribution agreements. Recent distributor wins include Permedica for Italy and North Africa, Droguepar S.A for Paraguay, and Artimedica for Mexico, complementing KOL-led clinical demonstration programs in Taiwan, Japan, and Egypt.

### What investment stages or asset classes does CUREXO target?

As a commercial manufacturer, CUREXO does not target investment stages. Its capital deployment occurs through internal R&D, regulatory filings (FDA, CE MDR, COFEPRIS, and other local clearances), and direct sales-channel expansion. The hardware portfolio spans three device families: CUVIS-joint, CUVIS-spine, and MorningWalk.

### Which geographies does CUREXO actively sell into?

CUREXO sells into Asia (South Korea, Japan, India, Taiwan), Latin America (Brazil, Paraguay, and recently approved entry into Mexico), Europe (Italy, with CE MDR certification enabling broader EU distribution), and North Africa (Morocco and Egypt via Permedica and local partners). The US market is accessible via its FDA clearance.

### Does CUREXO participate in fund commitments or co-investments alongside external GPs?

No. CUREXO’s capital goes into product development, manufacturing, and geographic commercialization. The firm does not allocate to fund commitments, direct private-company investments, or co-investment vehicles of any kind.

### How does the open-platform implant strategy affect CUREXO’s competitive position?

CUREXO designed CUVIS-joint to work with multiple implant manufacturers rather than locking hospitals into a proprietary implant system. This strategy allows CUREXO to partner with established implant companies in different regions — Permedica in Italy, for example — and accelerates hospital adoption where surgeons want to maintain their existing implant preferences while adding robotic-assisted precision.

## Related profiles

- [Jasaya Investments](https://altss.com/profile/jasaya-investments)
- [University of Maryland](https://altss.com/profile/university-of-maryland)

---

Last updated: 2026-07-10T22:16:45.000Z

Canonical page: https://altss.com/profile/curexo

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology